CTOs on the Move

Cedilla Therapeutics

www.cedillatx.com

 
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cedilla Therapeutics raised $56.2M on 04/24/2018

Similar Companies

Artel

Artel is the global technology leader in ultra low volume liquid delivery measurement and quality assurance. The company develops and manufactures the most accurate, precise and easy-to-use systems available for ensuring liquid delivery data integrity and NIST-traceable results in life sciences laboratories. Artel innovations help laboratories improve processes and increase productivity, enhance product quality, and address compliance challenges.

Highmark Delaware

Highmark Delaware is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Selecta Biosciences

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by avoiding unwanted immune responses. Selecta`s tolerogenic Synthetic Vaccine Particles (SVP™) technology platform is designed to enable a range of novel biologics for rare and serious diseases that require new treatment options. The company`s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company`s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta`s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts.

DNA Direct

DNA Direct is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boccard Usa Corporation

Boccard Usa Corporation is a Sugar Land, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.